USPTO serial 79288213
CURIGIN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 14, 2021
- Examiner
- BRADLEY, EVELYN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with CURIGIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,046*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Eric S. Hyman
Eric S. Hyman Womble Bond Dickinson (US) LLP12400 Wilshire BoulevardSuite 600Los Angeles, CA 90025Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biopharmaceuticals for the prevention of cancer; biopharmaceuticals for the diagnosis of cancer; biopharmaceuticals for the treatment of cancer; biopharmaceuticals in the form of cancer oncolytic virus for the prevention of cancer; biopharmaceuticals in the form oncolytic virus for the diagnosis of cancer; biopharmaceuticals in the form of oncolytic virus for the treatment of cancer; Drugs for medical purpose for the treatment of cancer and non-cancerous diseases, namely, respiratory, metabolic, neurological, ophthalmological, gastrointestinal, cardiovascular, skin, urogenital, gynecological, endocrine, head and neck, skeletal, autoimmune and rare diseases; Veterinary preparations for the treatment of cancer and non-cancerous diseases, namely, respiratory, metabolic, neurological, ophthalmological, gastrointestinal, cardiovascular, skin, urogenital, gynecological, endocrine, head and neck, skeletal, autoimmune and rare diseases; anti-cancer preparations; antiulcerants; vaccines; pharmaceutical preparations and substances for the prevention of cancer; viral and non-viral vector-based pharmaceutical products for the treatment of cancer; viral and non-viral vector-based pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical compounds for treating cancer; pharmaceuticals for viral and non-viral vector-based gene therapy; medicine for viral and non-viral vector-based gene therapy for human purposes; antibiotics; dietary supplements; dietetic nutritionally fortified food adapted for medical purposes; insecticides; fungicides | ACTIVE | — |
| 035 | Providing commercial information and consumer product information; import-export agency services; sales agency services, namely, sales promotion for others in the field of apparatus for use in medical analysis; arranging sales events for others in the field of apparatus for use in medical analysis; sales agency services, namely, sales promotion for others in the field of pharmaceuticals; arranging sales events for others in the field of pharmaceuticals; business intermediary services in the nature of purchasing pharmaceuticals for others relating to mail order by telecommunications; procurement of contracts for the purchase and sale of goods and services; advertising services; advertising services relating to pharmaceutical products; business intermediary services in the nature of matching purchasers with sellers of goods and services for the sale and purchase of goods and services | ACTIVE | — |
| 042 | Research relating to biotechnology; scientific research for medical purposes in the field of cancerous diseases; research relating to pharmaceuticals; research in the field of medical products; medical research services; conducting clinical trials for others; clinical studies in the nature of medical research; development of new technology for others in the field of biotechnology; scientific research for medical purposes in the area of cancerous diseases; development of medical products; development of pharmaceutical preparations and medicines; pharmaceutical drug development services; conducting clinical research in the field of medicines; clinical trials of medicines, for others; software design and development; computer programming for others in the medical field | ACTIVE | — |
| 044 | Providing health information, not including dentistry; healthcare information services relating to the use of medical products for the prevention, diagnosis and treatment of cancer and non-cancerous diseases; medical and pharmaceutical consultancy; consultancy services relating to pharmaceutical products for the prevention, diagnosis and treatment of cancer and non-cancerous diseases; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceutical products for the prevention, diagnosis and treatment of cancer and non-cancerous diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Curigin Co., Ltd
- Other trademarks owned by Curigin Co., Ltd
- Other trademarks owned by Curigin Co., Ltd
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CURIGIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 21, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 25, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 24, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 14, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 19, 2021 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 14, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 1, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 1, 2021 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 25, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 28, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 28, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 22, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 22, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Sep 8, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 25, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 25, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 25, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 25, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 25, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 9, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 9, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 9, 2021 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 8, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 8, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 8, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 25, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 25, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 25, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 27, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 5, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 25, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 19, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 18, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 13, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 30, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 26, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 25, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |